Abstract:It is impossible to ignore the rapidly growing interest in the therapeutic use of psychedelics. Once marginalized as elements of counterculture, substances such as lysergic acid diethylamide (LSD) have catapulted into the limelight. Traditionally, psychedelic therapy has involved administering "macro" doses, leading to potent psychoactive effects (the psychedelic "trip"). Although these effects are assumed to have therapeutic merits some argue that they may limit the broader application of these emerging interventions [1]. "Microdosing", an alternative approach that involves taking sub-hallucinogenic doses of psychedelics for mental health benefit, is being evaluated in clinical populations. At the same time, mechanisms of effects of psychedelics (both macro and microdosed) are being evaluated. In this context, the recent report by Murray et al. published in Neuropsychopharmacology is a relevant contribution to the field [2]. Pooling data from three previous studies, the authors evaluated the relationship between electroencephalography (EEG) measures of neural complexity across drug classes and doses in healthy participants. Neural complexity refers to the diversity and richness of brain activity patterns. It is hypothesized that serotonin 2A receptor (5-HT 2A ) receptor agonism induces changes in neural complexity during the subjective psychedelic experience, serving as a key mechanism for therapeutic effects [2]. Murray et al. conducted a secondary analysis involving 73 healthy adults that compared microdoses of either LSD (13 and 26 μg), tetrahydrocannabinol (THC) (7.5 and 15 mg), or methamphetamine (10 and 20 mg) against placebo. Each participant underwent three sessions during which they received either a placebo or one of two doses of the respective drugs. They assessed clinical measures including the 5 Dimensions of Altered State of Consciousness (5D-ASC), a self-reported measure of the subjective psychedelic experience, and EEG measures of neural complexity (Limpel-Ziv Complexity).

The serotonergic psychedelic N,N-dipropyltryptamine alters information-processing dynamics in in vitro cortical neural circuits

The serotonergic psychedelic N,N-dipropyltryptamine alters information-processing dynamics in cortical neural circuits

Transient destabilization of whole brain dynamics induced by DMT

A lasting impact of serotonergic psychedelics on visual processing and behavior

Robust Methods For Quantifying Neuronal Morphology And Molecular Signaling Reveal That Psychedelics Do Not Induce Neuroplasticity

Neural effects of psychedelics: Complexity the key word

Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain

Time-resolved neural and experience dynamics of medium- and high-dose DMT

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Psilocybin desynchronizes the human brain

Tryptamine psychedelics shape population receptive fields in early visual cortex in the presence of perceptual distortions

Enhanced repertoire of brain dynamical states during the psychedelic experience

Neurochemical and Neurophysiological Effects of Intravenous Administration of N,N-dimethyltryptamine in Rats

Neural geometrodynamics, complexity, and plasticity: a psychedelics perspective

Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin

Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields

Psilocybin desynchronizes brain networks

Neural mechanisms of psychedelic visual imagery